论文部分内容阅读
目的:评价养血清脑颗粒联合川芎嗪注射液治疗脑梗死风痰入络证疗效。方法:将符合入选标准的2019年1－12月濉溪县中医医院96例脑梗死风痰入络证患者，采用随机数字表法分为2组，每组48例。对照组静脉注射川芎嗪注射液，观察组在对照组治疗基础上加服养血清脑颗粒。2组均连续治疗2周。分别于治疗前后进行中医证候评分，采用美国国立卫生研究院卒中量表（National Institutes of Health Stroke Scale，NIHSS）评估神经功能缺损程度，采用日常生活活动量表（Activity of Daily Living Scale，ADL）评价患者生活质量，以全自动血液流变仪检测全血高切黏度、低切黏度及血浆黏度，评价临床疗效。结果:观察组总有效率为95.8%（46/48）、对照组为70.8%（34/48），2组比较差异有统计学意义（n χ2=9.08，n P<0.01）。治疗后，观察组中医证候评分低于对照组（n t=3.51，n P<0.01），NIHSS评分低于对照组（n t=34.41，n P<0.01），ADL评分高于对照组（n t=57.88，n P<0.001）。治疗后，观察组全血高切黏度［（5.04±0.93）mPa?s比（5.64±1.13）mPa?s，n t=2.84］、全血低切黏度［（11.32±1.74）mPa?s，比（13.39±2.23）mPa?s，n t=5.07］及血浆黏度［（1.51±0.33）mPa?s比（1.73±0.47）mPa?s，n t=2.65］低于对照组（n P<0.05或n P<0.01）。n 结论:养血清脑颗粒联合川芎嗪注射液可有效改善脑梗死风痰入络证患者的神经功能状态及生活质量，提高临床疗效。“,”Objective:To evaluate the clinical efficacy of n Yangxue-Qingnao granule combined with ligustrazine injection in the treatment of wind-phlegm entering collaterals syndrome of cerebral infarction.n Methods:A total of 96 patients with cerebral infarction and wind-phlegm entering collaterals syndrome to Suixi County Hospital of Traditional Chinese Medicine from January 2019 to December 2019 were selected and randomly divided into two groups by random number table method, with 48 in each group. The control group was given intravenous ligustrazine injection, and the observation group was given n Yangxue-Qingnao granule on the basis of the treatment of the control group. Both groups were treated continuously for 2 weeks. TCM syndrome scores were performed before and after treatment, the National Institutes of Health Stroke Scale (NIHSS) was used to assess the degree of neurological impairment, and the Activity of Daily Living Scale (ADL) was evaluated. To evaluate the patient\'s quality of life, to detect the high-shear viscosity, low-shear viscosity and plasma viscosity of whole blood with an automatic hemorheology instrument.n Results:The total effective rate of the observation group was 95.8% (46/48) and that of the control group was 70.8% (34/48). The difference between the two groups was statistically significant (n χ2=9.08, n P<0.01). After treatment, the TCM syndrome score of the observation group was significantly lower than that of the control group (n t=3.51, n P<0.01), the NIHSS score was significantly lower than that of the control group (n t=34.41, n P<0.001), and the ADL score was significantly higher than that of the control group (n t=57.88, n P<0.01). After treatment, the observation group\'s whole blood high shear viscosity [(5.04 ± 0.93)mPa?sn vs. (5.64 ± 1.13)mPa?s, n t=2.84], whole blood low shear viscosity [(11.32 ± 1.74)mPa?s n vs. (13.39 ± 2.23)mPa?s, n t=5.07] and plasma viscosity [(1.51 ± 0.33)mPa?s n vs. (1.73 ± 0.47)mPa?s, n t=2.65] of the observation group were significantly lower than those in the control group (n P<0.05 orn P<0.01).n Conclusion:Yangxue-Qingnao granule combined with ligustrazine injection can improve the neurological status and quality of life of patients with cerebral infarction syndrome of wind-phlegm entering the collaterals, and improve the clinical efficacy.n